'Pcsk9 inhibitors' presentation slideshows

Pcsk9 inhibitors - PowerPoint PPT Presentation

S.H.R Ghafelehbashi M.D Shahid Beheshti medical unioersity 30 october 2017

S.H.R Ghafelehbashi M.D Shahid Beheshti medical unioersity 30 october 2017

S.H.R Ghafelehbashi M.D Shahid Beheshti medical unioersity 30 october 2017. Expert consensus documents are intended to provide guidance for clinicians in areas where evidence may be limited are new and evolving or lack sufficient data. ACC Presidential Task Force. 2014.

★ ★ ★ ★ ★

1.69k views • 152 slides
PCSK9 Inhibition: LDL Lowering

PCSK9 Inhibition: LDL Lowering

PCSK9 inhibitors New option for dyslipidemia. PCSK9 Inhibition: LDL Lowering. Alireza Esteghamati,MD November 2018. Agenda. Residual risk after Statin PCCSK9 Inhibitors physiology & mechanism of action PCSK-9 Inhibitor trials: FOURIER, ODYSSEY , GLAGOV

★ ★ ★ ★ ★

1.49k views • 96 slides
Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA. Goal. Statin Intolerance. Serial IVUS. Effect on CHD Events of Lowering LDL-C. Percent Change in LDL-C During Treatment. Primary Endpoint: PAV. Percent of Patients Showing Regression in PAV.

★ ★ ★ ★ ★

435 views • 34 slides
American Heart Association Scientific Sessions

American Heart Association Scientific Sessions

American Heart Association Scientific Sessions. Importance of Targeting LDL-C. Trial Designs Compared Statins. Are Statins Enough?. Residual Risk Poorly Managed. PCSK9 Inhibitors. How Low is Too Low?. Please join us as we move on to the next interview. PCSK9 Inhibitors Clinical Trials.

★ ★ ★ ★ ★

409 views • 29 slides
PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation. Genetics PCSK9. PCSK9-Directed Therapies in Development. Alirocumab (SAR236553) Change in LDL-C at 2- and 4-Week Dosing Intervals on Atorvastatin.

★ ★ ★ ★ ★

596 views • 25 slides
PCSK9 Loss-of-function Mutations

PCSK9 Loss-of-function Mutations

PCSK9 Loss-of-function Mutations. PCSK9-Mediated Degradation of LDL-R. Evolution of Therapeutic Monoclonal Antibodies. Effect of PCSK9 Inhibitors on LDL-C in Heterozygous FH. DESCARTES % Change in LDL-C From Baseline at Week 52 in Patients With Hypercholesterolemia.

★ ★ ★ ★ ★

584 views • 19 slides
Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies

Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies

Cardiovascular Risk Management in Dyslipidemia: Clinical Controversies. Statin Intolerance. PROVE-IT TIMI 22. Familial Hypercholesterolemia. Estimated Rates of FH Diagnoses. LDL Hypothesis. Impact of PCSK9 on LDL Receptor Expression. PCSK9 Inhibitors. Abbreviations. Abbreviations (cont).

★ ★ ★ ★ ★

335 views • 18 slides
Patient Presentation

Patient Presentation

Patient Presentation. 2013 ACC/AHA Cholesterol Guidelines 4 Major Statin Benefit Groups. Timelines of Lipid-Lowering Agents. Evolution of Therapeutic Monoclonal Antibodies. PCSK9 Inhibition in Patients With Hypercholesterolemia Receiving Statin Therapy.

★ ★ ★ ★ ★

386 views • 16 slides
Dadu, R. T. & Ballantyne, C. M. (2014) Lipid lowering with PCSK9 inhibitors

Dadu, R. T. & Ballantyne, C. M. (2014) Lipid lowering with PCSK9 inhibitors

Figure 2 Ongoing phase III clinical trials of PCSK9 inhibitors. Dadu, R. T. & Ballantyne, C. M. (2014) Lipid lowering with PCSK9 inhibitors Nat. Rev. Cardiol. doi:10.1038/nrcardio.2014.84.

★ ★ ★ ★ ★

408 views • 1 slides

View Pcsk9 inhibitors PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Pcsk9 inhibitors PowerPoint presentations. You can view or download Pcsk9 inhibitors presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.